A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types  by Bzhalava, Davit et al.
Virology 445 (2013) 224–231Contents lists available at ScienceDirectVirology0042-68
http://d
n Corr
Laborat
Fax: +4
E-mjournal homepage: www.elsevier.com/locate/yviroA systematic review of the prevalence of mucosal and cutaneous
human papillomavirus types
Davit Bzhalava a, Peng Guan b, Silvia Franceschi b, Joakim Dillner a,b,n, Gary Clifford b
a International HPV Reference Center, Deptartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
b Section of Infections and Cancer, International Agency for Research on Cancer, Lyon, Francea r t i c l e i n f o
Article history:
Received 26 June 2013
Returned to author for revisions
8 July 2013
Accepted 16 July 2013
Available online 5 August 2013
Keywords:
Epidemiology
Meta analysis
Skin cancer
Cervical cancer22/$ - see front matter & 2013 Elsevier Inc. A
x.doi.org/10.1016/j.virol.2013.07.015
esponding author at: International HPV Refer
ory Medicine, Karolinska Institutet, Stockholm
6 40 337312.
ail address: joakim.dillner@ki.se (J. Dillner).a b s t r a c t
Systematic reviews of the prevalence of different types of Human Papillomavirus (HPV) across a broad
range of disease grades from normal to cancer are essential to gain basic knowledge of how widespread
infections with the different HPV types are, and to provide information on the possible carcinogenicity of
different HPV types. For HPV types that infect human mucosa, of which 12 are established causes of
cervical cancer, we present the results of a systematic review and meta-analysis of 47 HPV types in
cervical samples across the entire range of cervical diagnoses from normal to cervical cancer, restricted to
studies using a number of well characterized PCR assays.
For the cutaneous HPV types, which have been linked to the development of squamous cell
carcinoma of the skin, their presence has been measured in a variety of different sample types and by
assays with variable performance. Therefore, we restricted a systematic review of their prevalence to
studies that assayed for cutaneous HPV infection in a case-control format.
& 2013 Elsevier Inc. All rights reserved.Introduction
Human papillomaviruses (HPVs) are a large and diverse group
of viruses with 174 completely characterized types, with new HPV
types being continuously found (Bernard et al., 2010; Bottalico
et al., 2011; Chen et al., 2007; Chouhy et al., 2010; Ekstrom et al.,
2011; Ekstrom et al., 2010; Foulongne et al., 2012; Kohler et al.,
2011; Li et al., 2012; Nobre et al., 2009; Vasiljevic et al., 2008;
Vasiljevic et al., 2007). There are ﬁve major HPV genera: Alpha-
papillomavirus, Betapapillomavirus, Gammapapillomavirus, Mu
papillomavirus and Nu papillomavirus. HPVs infect epithelial cells
in genital mucosa (alphapapillomaviruses only), oral mucosa or
skin (representatives of all ﬁve genera). HPV types belonging to
different genera have less than 60% similarity, based on the
nucleotide sequence of the capsid protein L1. Different viral
species within a genus share between 60 and 70% similarity. A
novel HPV type has less than 90% similarity to any other HPV type
(de Villiers et al., 2004). Novel HPV types are given a number only
after the whole genome has been cloned and deposited with
the International HPV Reference Center (Bernard et al., 2010;
de Villiers et al., 2004), which was established in Heidelberg byll rights reserved.
ence Center, Deptartment of
, Sweden.Dr. Ethel-Michele deVilliers in 1985 and transferred to the
Karolinska Institutet in 2012 (www.hpvcenter.se).
HPVs cause a wide range of diseases from benign lesions to
invasive tumors (Duensing and Munger, 2004; Munoz et al., 2003).
In 2009, an International Agency for Research on Cancer (IARC)
working group classiﬁed 12 mucosal HPV types (HPV16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58 and 59) as carcinogenic to humans (Group
1) (Schiffman et al., 2009; IARC, 2012) for their association with
cervical cancer, hereafter also referred to as high-risk (HR) HPV
types. These 12 types cluster together in the same evolutionary
branch or “high-risk clade” that includes Alphapapillomavirus
species groups 5, 6, 7, 9 and 11. Eleven additional types in the
high-risk clade were classiﬁed as possibly carcinogenic (Group 2B)
based upon their phylogenetic relatedness to Group 1 types,with
the exception of HPV68, which was upgraded to probably carcino-
genic (Group 2A). Other mucosal HPV types in the Alphapapillo-
mavirus genus e.g. HPV6 and 11, can cause benign genital
condylomas (Bernard et al., 2010).
The cutaneous HPV types are commonly found in several skin
lesions such as benign skin warts (Pﬁster and Ter Schegget, 1997),
actinic keratoses (AKs), non-melanoma skin cancers (NMSCs)
(Curado et al., 2008) and keratoacanthomas (KAs) (Asgari et al.,
2008; Forslund et al., 2003a). Cutaneous HPV types are also
commonly detected on healthy skin (Forslund et al., 2004).
NMSCs such as squamous cell carcinoma (SCC) and basal cell
carcinoma (BCC) are two of the most prevalent cancers among
Caucasian populations worldwide (Oberyszyn, 2008). Ultraviolet
D. Bzhalava et al. / Virology 445 (2013) 224–231 225radiation is a well-known risk factor (Alam and Ratner, 2001), but
there may also be other risk factors (Boukamp, 2005; Reichrath,
2006). The increased incidence of SCC in immunocompromised
individuals has suggested that an infection may be involved (Berg
and Otley, 2002; Boukamp, 2005; Grulich et al., 2007; Lindelof
et al., 2000), with HPV being the most commonly studied
candidate infectious agent (Asgari et al., 2008; Forslund et al.,
2007). Skin samples from SCC, AK, seborrheic keratosis (SK), and
BCC commonly contain multiple HPV types, but typically at very
low viral loads (Ekstrom et al., 2010; Forslund et al., 2003a, 2003b;
Kullander et al., 2008; Vasiljevic et al., 2007, 2008). Cutaneous
HPV types have also been implicated in the etiology of squamous-
cell carcinoma of the conjunctiva (Ateenyi-Agaba et al., 2010).
Because of the extreme diversity of HPV types, it is an
enormous undertaking to obtain an exact epidemiologic deﬁnition
of which individual HPV types are associated with which diseases.
In the ﬁeld of mucosal HPV types, the use of cross-sectional meta-
analyses across different disease grades have long been key to
describing HPV type-speciﬁc prevalences and establishing the
causality of individual HPV types with cervical cancer (Guan
et al., 2013; Schiffman et al., 2009). Hence, in the present paper,
we expanded a recently published meta-analysis that reported the
prevalence of the 13 established or probably carcinogenic HPV
types across the full spectrum of cervical diagnoses from normal
cytology to cancer (Alam et al., 2003; Guan et al., 2013) to describe
all other mucosal HPV types, many of which have been tested for
in a smaller number of studies and samples than the most
frequent high-risk types.
We reasoned that a systematic review of type-speciﬁc preva-
lences might be useful also for the cutaneous HPV types. However,
the spectrum of pre-malignant lesions is less well understood in
the skin than in the cervix. In addition, in the ﬁeld of cutaneous
HPV types, the variety in different types of samples and assays
used meant that the simple pooling of prevalences from
unmatched studies might be misleading. We therefore present a
systematic review restricted to case-control studies that have
investigated exposure to cutaneous HPV types in skin cancer cases
and controls. Differences in types of sample and assays used would
then be affecting both cases and controls in different studies, and
could be adjusted for. Although this design is not bias-free, e.g. if
assays have low speciﬁcity or non-informative types of samples
have been tested, these biases will typically be conservative,
biasing any association towards the null.Results
Mucosal HPV types
Four hundred and twenty-three studies met eligibility criteria,
including a total of 371,951 eligible women. HPV type-speciﬁc
prevalence is presented for 47 mucosal HPV types across eight
grades of cervical diagnosis in Table 1. Overall HPV prevalence
increased with increasing severity of cervical disease from 12.6% in
normal cytology to 89.5% in ICC (Table 1). HPV16 was by far the
most frequently detected type in every grade. Among women with
normal cytology, type-speciﬁc prevalence ranged from 0.4 to 2.6%
for Group 1 (HR) types, from 0.1 to 1.1% for Group 2A/2B types and
from o0.1 to 1.1% for Group 3 types.
All 13 HPV types classiﬁed as established or probably carcino-
genic (Group 1/2A) by IARC were more commonly found among
patients with ICC than among subjects with normal cytology
(Table 1). Indeed, the prevalence of HPV16, HPV18 and 45 were
higher in ICC than in any other grade of cervical diagnosis. Other
carcinogenic types, however, were more frequently detected in
intermediate cervical diagnoses than in ICC. Particular examplesincluded HPV51 detected in 9.4 and 8.1% of LSIL and CIN1
respectively compared to only 1% of ICC, HPV52 detected in 10.1,
14.1 and 9.6% of CIN1, 2 and 3 respectively, compared to 3.2% of
ICC, and HPV31 detected in 10.0 and 10.8% of CIN2 and CIN3
respectively compared to 3.5% of ICC.
Some HPV types classiﬁed as probably or possibly carcinogenic
(Group 2A/2B), namely HPV26, 67, 68, 69, 73 and 82, were also
more common in ICC than in normal cytology. Other Group 2A/2B
types, for example HPV53 and 66, were more common in normal
cytology than ICC and were also found in a higher proportion of
low-grade diagnoses (e.g. 8.4 and 7.7% of LSIL respectively) than
ICC (0.5 and 0.3% respectively).
Among other HPV types, that were relatively uncommon in
normal cytology and invasive cancer, many were commonly
detected in intermediate diagnoses, in particular the alpha-9 types
61, 62, 84 and 89.
The addition of individual type-speciﬁc prevalences within
each disease grade produced totals well above above 100% for all
diagnoses known to be caused by HPV, highlighting the frequent
presence of multiple HPV types within the same women. Indeed,
in a subset-analysis of studies providing the necessary data
breakdown, the prevalence of multiple infections ranged from
12% in ICC up to 39% in CIN2.
Cutaneous HPV types
The initial search identiﬁed 41200 studies. After scanning of
titles and abstracts, 119 studies were retained. Detailed investiga-
tion of abstracts identiﬁed 18 studies assessing exposure to
cutaneous HPV types among patients with skin cancers (SCC,
BCC) or precursor lesions (AK). Three studies (Feltkamp et al.,
2003; Masini et al., 2003; Struijk et al., 2003) were excluded
because the populations were overlapping. Finally 15 studies were
included in the analysis.
Among the included studies, nine used hospital-based case-
control design (Andersson et al., 2008; Asgari et al., 2008; Forslund
et al., 2007; Iannacone et al., 2012, 2013; Stark et al., 1998; Steger
et al., 1990; Struijk et al., 2006; Waterboer et al., 2008), one study
used hospital-based case-control design among organ transplant
patients (OTR) (Proby et al., 2011), four studies used a population
based design to identify cases and controls (Andersson et al., 2012;
Casabonne et al., 2007; Karagas et al., 2006; Termorshuizen et al.,
2004) and two studies used a prospective follow-up study design
(Plasmeijer et al., 2011; Andersson et al., 2012).
Results comparing prevalence of cutaneous HPV types in cases
and controls are shown in Table 2. There have been few studies of
cutaneous HPV types in the alpha genus.
For the beta genus, there have been a large number of studies
of SCC using serology and/or detection of HPV DNA using various
sample types. Upon combination of types at the species level, the
prevalence of species Beta-1, Beta-2 and Beta-3 were each sig-
niﬁcantly elevated in SCC compared to controls, both using
serology and DNA detection. At the individual type level, the
prevalence of antibodies against HPV8 (Beta-1), HPV15, HPV17,
HPV38 (Beta-2), HPV49 and HPV76 (Beta-3) were elevated in SCC
in comparison to controls, but corresponding differences for DNA
detection did not meet statistical signiﬁcance. In contrast, the
prevalence of DNA of HPV24 (Beta-1) was signiﬁcantly higher in
SCC than controls, but the corresponding difference in antibody
prevalence did not meet statistical signiﬁcance. Species Beta-4 was
represented only by HPV92, for which DNA was signiﬁcantly more
prevalent in SCC than in controls (Table 1).
Data on HPV types of genus Gamma, Mu and Nu were fewer
than for beta-types, deriving only from serology studies, and
showed no signiﬁcant differences in seroprevalence between cases
and controls at an individual HPV type level, even if OR estimates
Table 1
Type-speciﬁc prevalence of mucosal HPV DNA, by grade of cervical diagnosis.
HPV
species
HPV
type
IARC
classiﬁcation
Normal ASCUS LSIL HSIL CIN1 CIN2 CIN3 ICC
N
tested
%pos N
tested
%pos N
tested
%pos N
tested
%pos N
tested
%pos N
tested
%pos N
tested
%pos N
tested
%pos
Any 263971 12.6 13178 52.1 19456 75.2 7727 85.3 10030 74.2 4809 85.4 11679 92.4 41101 89.5a
Alpha-9 HPV16 1 263971 2.6 13178 12 19456 19.5 7727 40.5 10030 19.2 4809 34 11679 53.8 41101 55.8a
Alpha-7 HPV18 1 263702 1 13161 4.7 19447 6.3 7711 8.2 9883 7 4735 8.7 11583 6.9 41164 14.3a
Alpha-7 HPV45 1 243656 0.6 11591 2.9 14957 3.3 5901 3.9 8527 3 4344 4.3 10030 3.4 33997 4.8a
Alpha-9 HPV33 1 254120 0.6 12218 3 18617 4.9 7431 7.1 9176 3.7 4617 7.1 11121 8.5 37700 4.0a
Alpha-9 HPV58 1 247990 0.8 11790 3.9 15052 5.5 6108 6.9 8762 7.1 4420 10.3 10322 8.4 35539 4.0a
Alpha-9 HPV31 1 252392 1 12191 4.7 18546 7.9 7293 9.4 9193 6.8 4754 10 11254 10.8 36769 3.5a
Alpha-9 HPV52 1 239298 1 10288 5.4 13016 6.5 5268 8.6 8546 10.1 4486 14.1 10399 9.6 34939 3.2a
Alpha-9 HPV35 1 237554 0.4 10181 3 14566 3.8 5465 5 8763 2.8 4429 4.3 10221 3.3 33690 1.6a
Alpha-7 HPV39 1 235758 0.6 10306 4.2 12723 5.5 5003 3.8 8214 4.9 4206 4.7 9730 3.1 32277 1.3a
Alpha-7 HPV59 1 235145 0.4 9998 3.1 12691 4.3 5270 2.7 8128 3.7 4118 4 9767 2.1 33277 1.2a
Alpha-5 HPV51 1 235223 0.9 10490 4.8 12681 9.4 5410 6 8320 8.1 4230 8.4 9833 5.1 32333 1.0a
Alpha-6 HPV56 1 241829 0.6 10541 3.5 12949 7 5119 3.1 8327 5.6 4261 3.7 10044 2.3 32383 0.8a
Alpha-7 HPV68 2A 231085 0.4 9593 1.8 11647 2.2 4701 1.8 8315 2.3 3988 2.5 7956 1.9 29471 0.5a
Alpha-6 HPV53 2B 138289 1.1 8409 5.4 9502 8.4 4404 4 7445 6.4 3714 4.5 8644 3.1 28864 0.5
Alpha-11 HPV73 2B 116913 0.3 7216 1.9 8452 2.7 3782 2.5 4954 2.3 3184 2.1 5923 1.8 25848 0.5a
Alpha-10 HPV6 144585 0.8 10309 3.1 12945 5.9 5240 2.7 6354 6 3710 3 8762 1.7 32074 0.4
Alpha-10 HPV11 144039 0.5 10278 1.6 12738 2.9 5186 0.9 6205 2.5 3547 1.4 8360 0.8 31126 0.4
Alpha-3 HPV62 65761 1.0 6092 4.4 5719 4.1 2798 3.3 3264 6.1 2404 4.1 5711 2.3 6490 0.4
Alpha-13 HPV54 128177 0.6 7914 2.4 8570 2.9 3636 2.7 6152 2.6 2873 3.2 6945 2 12174 0.3
Alpha-6 HPV66 2B 204436 0.6 9446 4 11602 7.7 4788 3.5 7642 5.9 3871 4.6 9317 2.4 30959 0.3
Alpha-9 HPV67 2B 83910 0.2 6242 1.2 5975 1.8 2461 1.1 3304 1.9 2472 1.5 6014 0.7 20661 0.3a
Alpha-3 HPV84 106816 0.5 7273 2.8 7365 3.1 3086 3.2 3895 3.3 2739 3 5964 1.8 8111 0.3
Alpha-5 HPV26 2B 107818 0.1 7043 0.5 7134 0.4 3226 0.5 4997 0.6 2822 1.1 6692 0.5 26459 0.2a
Alpha-6 HPV30 2B 26559 0.1 620 0.5 1603 0.3 477 0 811 0.6 244 0.4 408 0.5 13763 0.2a
Alpha-5 HPV69 2B 76797 0.1 5210 0.2 5888 0.3 2336 0.3 3320 0.3 2219 0.4 5615 0.4 17929 0.2a
Alpha-7 HPV70 2B 117590 0.8 6596 2.4 7587 2.3 3348 2.1 5819 1.5 2994 1.7 7480 1.1 27802 0.2
Alpha-3 HPV81 100495 0.6 6785 2.3 6884 2.8 3026 1.8 3410 2.9 2319 3.1 5918 1.1 9048 0.2
Alpha-5 HPV82 2B 132350 0.1 6783 1.2 8253 1.8 3886 2 5038 1.5 3316 1.8 7463 1.7 28105 0.2a
Alpha-11 HPV34/
64
2B 67241 0.1 5377 0.3 6462 0.3 2592 0.2 3869 0.2 2090 0 5682 0.1 22233 0.1
Alpha-1 HPV42 127999 0.5 7235 4.3 8388 4.8 4024 1.6 5966 3.3 2938 2.4 7162 1.2 22667 0.1
Alpha-10 HPV44 103820 0.4 2267 0.1 3399 0.3 2194 0.3 3997 1.2 2034 0.9 5500 0.4 21162 0.1
Alpha-10 HPV55 86033 0.3 6860 1.2 6184 2.2 2889 1.8 3210 1.4 1825 1.4 5074 1.2 7913 0.1
Alpha-3 HPV61 100536 0.6 6243 3.5 6561 3.8 3013 3.5 4399 2.7 2611 2.9 6322 2.2 20874 0.1
Alpha-14 HPV71 88989 0.4 5714 0.7 5189 0.4 2421 0.3 3524 0.3 2347 0.4 5805 0.4 8389 0.1
Alpha-3 HPV72 94406 0.3 6046 0.7 6133 0.8 2640 0.8 3198 0.5 2204 0.5 5745 0.6 9173 0.1
Alpha-3 HPV83 111587 0.4 6843 2.1 7377 1.9 3089 1.8 4092 2.2 2360 1.4 5696 1.5 9525 0.1
Alpha-3 HPV89 70578 0.4 4563 3 5161 3.4 2400 2.9 3092 5.2 1825 3.1 5242 2.3 8565 0.1
Alpha-14 HPV90 24901 0.6 322 1.9 1078 1.9 287 0.7 479 0.8 132 0.8 230 0.9 1853 0.1
Alpha-1 HPV32 56802 0.1 2675 0.3 2415 0.1 1066 o0.1 894 0.1 895 0.6 2314 0.1 3640 o0.1
Alpha-8 HPV40 91596 0.2 7328 0.9 7940 1.6 3685 0.6 5400 0.8 2622 1 6383 0.4 11224 o0.1
Alpha-8 HPV43 89787 0.3 2198 0.5 3498 0.3 2160 0.1 2182 0.4 822 0.2 4044 0.1 9535 o0.1
Alpha-4 HPV57 64170 o0.1 3526 0.1 4448 o0.1 1848 o0.1 1331 o0.1 589 o0.1 3854 0.1 6764 o0.1
Alpha-10 HPV74 60697 0.5 4762 0.2 3720 0.6 1288 0.8 1302 0.5 685 0.7 3540 0.1 4882 o0.1
Alpha-7 HPV85 2B 30197 0.2 1695 0.4 1036 0.4 561 0.5 1134 0.2 1018 0.3 1053 0.2 2549 o0.1
Alpha-3 HPV86 15299 0.1 254 0.4 562 0.4 220 o0.1 479 o0.1 132 o0.1 184 o0.1 1801 o0.1
Alpha-3 HPV87 5987 0.1 189 0.5 1032 0.2 260 0.4 478 0.4 129 o0.1 222 0.5 963 o0.1
Alpha-8 HPV91 5403 0.2 882 3.6 1069 4.2 355 3.1 603 2.5 272 2.6 281 2.5 11706 o0.1
Total 28.3 136.6 189.1 185.0 183.4 210.2 182.9 113.6
Multiple infection
(subset analysis)
158120 4.3 7411 21 9358 28 2914 28 5851 32 2734 39 6917 27 23929 12
a Higher prevalence in ICC than in normal cytology.
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However, upon combination of HPV types in the Gamma-1 species,
antibody prevalence was signiﬁcantly elevated in SCC versus
controls.
For AK, a SCC precursor, the detection of Beta-1 types was
signiﬁcantly higher in cases than controls, driven by a signiﬁcant
difference in the prevalence of HPV24 DNA, similar to that seen
for SCC.
In striking contrast to SCC, none of the cutaneous HPVs
appeared to be signiﬁcantly elevated in BCC in comparison to
controls, neither by serology nor DNA detection (Table 1).Discussion
Mucosal HPV types
The present systematic review is the ﬁrst to comprehensively
report the prevalence of the full range of mucosal HPV types across
the complete spectrum of cervical disease. We relied upon a
methodology already established in a previous review restricted
to the 13 established or probable HR HPV types (Guan et al., 2012).
However, whereas the previous review compared type-speciﬁc
prevalence among HR HPV-positive women only (with the speciﬁc
Table 2
Exposures to cutaneous HPV types and risk of non-melanoma skin cancers (SCC and BCC), or the precursor lesion AK. Subjects with healthy skin constituted the reference category.
Species Type SCC BCC AK
Serology PCR Serology PCR Serology PCR
Cases/
controls
%pos OR(95%CI) Cases/
controls
%pos OR(95%CI) Cases/
controls
%pos OR(95%CI) Cases/
controls
%pos OR(95%CI) Cases/
controls
%pos OR(95%CI) Cases/
controls
%pos OR(95%CI)
Alpha4 HPV2 687/80 10.2/10.0 1.2(0.9–1.8) 1990/ 5.4/ 0.9(0.7–1.1)
Alpha4 HPV27 687/80 12.5/12.5 1.2(0.8–1.6) 82/92 0.0/1.1 0.4(0.0–9.2) 1990/ 11.7/ 1.1(0.9–1.3) 126/92 0.0/1.1 0.2(0.0–6.0) 49/92 0.0/1.1 0.6(0.0–15.4)
Alpha4 HPV57 126/201 2.4/4.0 0.6(0.0–
14.4)
160/121 0.0/1.7 0.1(0.0–3.1) 81/121 2.5/1.7 1.5(0.2–10.9)
Alpha4
total
1.2(0.9–1.5) 0.4(0.0–9.2) 1.0(0.8–1.2) 0.2(0.0–6.0) 1.5(0.2–10.9) 0.6(0.0–15.4)
Beta1 HPV5 1737/
2897
13.9/11.0 1.4(1.0–1.8) 403/742 21.8/
17.4
1.3(0.8–2.0) 2899/
882
7.4/9.6 1.0(0.8–1.2) 81/121 19.8/
13.2
1.6(0.8–3.5) 90/45 35.6/
24.4
1.7(0.8–3.8)
Beta1 HPV8 1755/
3076
26.7/22.8 1.7(1.2–2.3) 489/835 15.5/
11.7
1.6(0.9–3.0) 2953/
1092
20.0/
16.8
1.3(0.8–2.1) 126/92 0.0/1.1 0.2(0.0–6.0) 183/167 22.4/
19.8
1.5(0.8–2.6) 110/128 2.7/2.3 0.8(0.2–4.0)
Beta1 HPV12 82/92 1.2/0.0 3.4(0.1–84.7)
Beta1 HPV14 82/92 2.4/1.1 2.3(0.2–25.6) 126/92 1.6/1.1 1.5(0.1–16.4) 49/92 0.0/1.1 0.6(0.0–15.4)
Beta1 HPV19 126/92 0.8/0.0 2.2(0.1–54.9)
Beta1 HPV20 1775/
2941
19.8/14.9 1.3(1.0–1.5) 480/833 14.0/
11.4
1.3(0.7–2.6) 2899/
882
13.3/
12.1
1.0(0.9–1.2) 126/92 2.4/7.6 0.3(0.1–1.2) 177/165 13.6/
9.7
1.5(0.7–3.2) 138/132 23.9/
9.8
1.4(0.3–7.9)
Beta1 HPV21 82/92 1.2/3.3 0.4(0.0–3.6) 126/92 2.4/3.3 0.7(0.1–3.7) 49/92 4.1/3.3 1.3(0.2–7.8)
Beta1 HPV24 1735/
2868
14.5/16.6 1.3(0.9–1.7) 483/837 25.9/
18.2
1.8(1.3–2.4) 2899/
882
8.2/9.0 1.0(0.7–1.4) 126/92 0.8/0.0 2.2(0.1–54.9) 177/169 11.9/
10.1
1.3(0.6–2.5) 137/133 22.6/
5.3
2.7(1.1–6.5)
Beta1 HPV36 1581/
2577
12.8/12.2 1.1(0.9–1.3) 204/377 44.6/
36.6
1.4(1.0–2.0) 2899/
882
8.7/9.9 0.9(0.8–1.1) 81/121 9.9/7.4 1.4(0.5–3.7)
Beta1 HPV93 301/534 7.0/6.9 1.0(0.6–1.8) 532/745 13.7/
13.2
1.1(0.8–1.7)
Beta1 total 1.3(1.2–1.5) 1.4(1.3–1.7) 1.0(0.9–1.2) 0.6(0.3–1.4) 1.4(1.0–2.0) 1.8(1.1–2.8)
Beta2 HPV9 1538/
2500
19.4/15.8 1.2(1.0–1.5) 286/469 22.7/
18.8
1.5(1.0–2.2) 2899/
882
14.4/
14.5
0.9(0.8–1.1) 126/92 0.8/1.1 0.7(0.0–11.8) 81/121 18.5/
18.2
1.3(0.6–3.0) 49/92 2.0/1.1 1.9(0.1–31.0)
Beta2 HPV15 1780/
2944
23.0/19.5 1.4(1.1–1.7) 485/836 14.8/
15.1
1.1(0.8–1.5) 3123/
1182
15.9/
15.7
1.0(0.8–1.4) 174/168 10.9/
13.7
0.9(0.5–1.8) 60/35 3.3/2.9 1.2(0.1–13.4)
Beta2 HPV17 1107/
834
26.4/22.5 1.4(1.1–1.7) 204/377 18.6/
17.2
1.1(0.7–1.7) 2214/
300
17.2/
25.7
1.1(0.9–1.3)
Beta2 HPV23 1214/
1918
15.4/14.2 1.2(0.9–1.7) 286/469 37.1/
36.9
1.3(0.9–1.8) 2214/
300
10.7/
20.3
1.1(0.9–1.4) 126/92 0.8/2.2 0.4(0.0–4.0) 49/92 0.0/2.2 0.4(0.0–7.8)
Beta2 HPV37 82/92 2.4/0.0 5.7(0.3–121.4) 126/92 0.8/0.0 2.2(0.1–54.9)
Beta2 HPV38 1656/
2743
24.2/24.4 1.4(1.2–1.6) 476/833 24.4/
20.3
1.3(0.7–2.4) 2739/
761
13.7/
16.3
1.0(0.8–1.2) 126/92 0.0/2.2 0.1(0.0–3.0) 81/121 18.5/
18.2
1.0(0.5–2.1) 134/141 21.6/
12.1
1.1(0.6–2.3)
Beta2 HPV80 82/92 2.4/0.0 5.7(0.3–121.4)
Beta2 HPV107 173/300 19.1/16.0 1.2(0.8–2.0) 224/300 14.7/
16.0
0.9(0.6–1.5)
Beta2 total 1.3(1.2–1.4) 1.3(1.1–1.5) 1.0(1.0–1.1) 0.5(0.1–2.0) 1.0(0.7–1.6) 1.1(0.6–2.1)
Beta3 HPV49 1107/
834
26.3/26.1 1.3(1.1–1.5) 286/469 9.4/8.3 1.3(0.8–2.2) 2214/
300
19.2/
29.7
1.1(0.9–1.3) 126/92 0.0/1.1 0.2(0.0–6.0) 49/92 2.0/1.1 1.9(0.1–31.0)
Beta3 HPV75 1107/
834
15.1/15.0 1.3(1.0–1.6) 204/377 14.2/
9.5
1.6(0.9–2.6) 2214/
300
9.5/
15.3
1.0(0.8–1.2)
Beta3 HPV76 1107/
834
15.1/15.9 1.4(1.1–1.8) 204/377 14.2/
8.8
1.7(1.0–2.9) 2214/
300
6.4/
18.0
0.9(0.7–1.3)
Beta3 total 1.3(1.2–1.5) 1.5(1.1–2.1) 1.0(1.0–1.1) 0.2(0.0–6.0) 1.9(0.1–31.0)
Beta4 HPV92 1107/
834
13.6/16.5 1.2(1.0–1.6) 204/377 14.7/
8.8
1.8(1.1–3.0) 2214/
300
7.3/
16.7
1.0(0.7–1.4)
Beta4 total 1.2(1.0–1.6) 1.8(1.1–3.0) 1.0(0.7–1.4)
Beta5 HPV96 860/380 16.6/15.5 1.1(0.8–1.4) 82/92 1.2/0.0 3.4(0.1–84.7) 2214/
300
12.5/
15.0
1.0(0.8–1.2)
Beta5 total 1.1(0.8–1.4) 3.4(0.1–84.7) 1.0(0.8-1.2)
Gamma1 HPV4 903/457 35.1/33.7 1.4(0.9–2.2) 2214/
300
33.0/
34.3
1.1(1.0–1.3)
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Table 2 (continued )
Species Type SCC BCC AK
Serology PCR Serology PCR Serology PCR
Cases/
controls
%pos OR(95%CI) Cases/
controls
%pos OR(95%CI) Cases/
controls
%pos OR(95%CI) Cases/
controls
%pos OR(95%CI) Cases/
controls
%pos OR(95%CI) Cases/
controls
%pos OR(95%CI)
Gamma1 HPV65 903/457 31.1/26.9 1.2(1.0–1.4) 2214/
300
25.5/
26.0
1.0(0.9–1.2)
Gamma1 HPV95 860/380 26.6/21.8 1.4(1.0–1.9) 2214/
300
21.2/
22.3
1.0(0.9–1.2)
Gamma1
total
1.3(1.1–1.5) 1.0(1.0–1.1)
Gamma2 HPV48 903/457 22.5/21.9 1.3(0.9–1.9) 2214/
300
15.0/
21.3
1.1(0.9–1.3)
Gamma2
total
1.3(0.9–1.9) 1.1(0.9–1.3)
Gamma3 HPV50 903/457 18.3/14.7 1.3(0.9–1.9) 2214/
300
14.0/
15.7
1.1(0.9–1.3)
Gamm3
total
1.3(0.9–1.9) 1.1(0.9–1.3)
Gamma4 HPV60 97/157 5.2/6.4 0.9(0.2–4.0)
Gamma4
total
0.9(0.2–4.0)
Gamma5 HPV88 173/300 7.5/6.7 1.1(0.6–2.3) 224/300 5.8/6.7 0.9(0.4–1.8)
Gamma5
Total
1.1(0.6–2.3) 0.9(0.4–1.8)
Gamma6 HPV101 860/380 6.4/9.2 1.1(0.8–1.6) 1990/ 2.6/ 0.9(0.6–1.2)
Gamma6 HPV103 860/380 7.6/4.7 1.5(1.0–2.2) 2214/
300
5.5/4.3 1.0(0.5–2.0)
Gamma6
total
1.3(1.0–1.7) 0.9(0.7–1.1)
Mu1 HPV1 932/501 27.4/27.1 1.3(0.8–2.1) 2374/
421
25.7/
28.0
1.1(1.0–1.3) 81/121 14.8/
18.2
0.8(0.4–1.7)
Mu1 total 1.3(0.8–2.1) 1.1(1.0–1.3) 0.8(0.4–1.7)
Mu2 HPV63 730/157 21.4/22.3 1.1(0.8–1.4) 1990/ 20.1/ 1.1(0.9–1.3)
Mu2 total 1.1(0.8–1.4) 1.1(0.9–1.3)
Nu1 HPV41 903/457 13.5/11.8 1.3(0.5–3.4) 2214/
300
12.3/
11.3
1.1(0.9–1.3)
Nu1 total 1.3(0.5–3.4) 1.1(0.9–1.3)
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D. Bzhalava et al. / Virology 445 (2013) 224–231 229aim to identify differences in the carcinogenic potential of HR HPV
types), we present type-speciﬁc prevalences for 47 mucosal HPV
types as a proportion of all tested women. This approach gives a
picture of the frequency of genital infection by HPV types in the
general female population (using women with normal cytology as
a proxy), and provides an estimate of the absolute fraction of
cervical abnormalities that are positive for different HPV types.
Lastly, data can also be used to compare the prevalence of HPV
types in various lesions with that in normal cytology, in a case:
control type of analysis, to give an estimate of causality.
HPV16 was shown to be by far the most common type in
women with normal cytology (2.6%), suggesting a substantial
advantage over all other mucosal HPV types in terms of transmis-
sibility and/or persistence. Other HR HPV types were detected in
0.4 to 1.0% of women with normal cytology. However, womenwith
normal cytology were also shown to be infected with a broad
range of other mucosal HPV types, with HPV53 (1.1%), 62 (1.0%), 70
(0.8%) and 6 (0.8%) being the most common.
The major novelty of the current review was to reveal the broad
range of non-HR HPV types that are commonly detected in low
and high-grade cervical abnormalities, and the very high preva-
lence of multiple infections in these lesions. Such a high propor-
tion of multiple infections has important implications for the
estimation of the fraction of low and high-grade cervical abnorm-
alities that are causally attributable to any one, or group, of
HPV types.
Nevertheless, by simple addition of type-speciﬁc prevalences,
the proportional impact of HPV-16/18 vaccination on cervical
lesions can be predicted to rise from 17% of ASCUS, through 49%
of HSIL, up to 70% of ICC. However, these estimates assume that all
HPV-16 and -18 are causally related to the lesion in which they are
found, even when another HPV type is present. This assumption
may lead to an over-estimation of the proportional impact,
particularly in low- and high-grade cervical abnormalities, where
many multiple infections with a broad range of HPV types are
involved. On the other hand, any cross-protection against other
HPV types might increase the proportional impact.
In conﬁrmation of their carcinogenic role, all HR HPV types
were signiﬁcantly more prevalent in ICC than in women with
normal cytology. Importantly however, in contrast to HPV16, 18
and 45, other HR HPV types were detected in a larger proportion
of intermediate diagnoses (e.g. HPV31, 52 and 58 each accounting
410% of CIN3) than in ICC, highlighting that the relative potential
of HR types to cause low- and high-grade abnormalities is not the
same as their relative potential to cause ICC. When comparing to
prevalences in LSIL or in CIN3, the only 3 HPV types that were
more common in ICC were HPV16, 18 and 45, emphasizing the fact
the among the different HR types these 3 types constitute a group
with particularly high ICC risks.
Lastly, a number of rare Group 2A/2B types, namely HPV26, 67,
68, 69, 73 and 82, were also more prevalent in ICC than normal
cytology. These types may eventually be considered for addition to
the list of Group 1-classiﬁed carcinogens and for becoming targets
for cervical cancer prevention.
Cutaneous HPV types
The systematic review of case-control studies on cutaneous
HPVs suggests that several HPV types in the Beta-1, Beta-2, Beta-3
and Beta-4 species are detected signiﬁcantly more often in SCC
than among controls, but that this is not the case for BCC. The
genus Gamma is a large and continuously growing HPV genus with
a plurality of HPV types that are each only rarely found. The
studies on HPV gamma viruses are therefore fraught with low
statistical power. However, the frequent ﬁnding of non-signiﬁcant
tendencies for increased risk does suggest that further studies onthe presence of HPV types of the genus Gamma in SCC are
warranted.
Interpretation of the data on cutaneous HPVs has a number of
potential problems, including the limitation of the type-speciﬁc
sensitivity and speciﬁcity of both serological and molecular assays
and distinguishing ﬁndings of high viral load from ﬁndings of less
than a viral copy per cell in skin cancer. At variance with the data
on prevalence of mucosal HPV types in the cervix, the distinction
of high-risk from low-risk cutaneous HPV types is in its infancy.Materials and methods
Mucosal HPV types
Identiﬁcation of studies
Methods have been described previously (Guan et al., 2012).
Medline was used to search for publications from January 1990 to
November 2011 using combinations of the MeSH terms: “cervical
cancer,” “cervical intraepithelial neoplasia,” “HPV,” “human,”
“female” and “polymerase chain reaction”. References cited in
retrieved articles were also evaluated. Eligible studies met the
following criteria: (i) use of broad-spectrum consensus PCR assays
based on the primers MY09/11, PGMY09/11, GP5+/6+, SPF10, SPF1/
GP6+ or L1C1/L1C2, and (ii) reporting of overall and type-speciﬁc
HPV prevalence by strata of cytopathological and/or histopatho-
logical cervical diagnoses (see deﬁnitions below).
For each included study, the following data were extracted by
cervical diagnosis: country, source of HPV DNA (cells versus
biopsies/tissue), PCR primers, sample size and overall and type-
speciﬁc prevalence of HPV DNA. If study methods suggested that
additional relevant information was available (e.g., additional HPV
types and/or more detailed stratiﬁcation by cervical diagnosis),
data requests were made to authors. For a subset of studies
reporting such data, the overall prevalence of multiple infections
was also extracted.
Cases were classiﬁed into eight grades of cervical diagnosis:
those diagnosed by cytology as (i) normal; (ii) ASCUS; (iii) low-
grade squamous intraepithelial lesion (LSIL) or (iv) high-grade
squamous intraepithelial lesion (HSIL); those diagnosed by histol-
ogy as (v) CIN1; (vi) CIN2 or (vii) CIN3 (including squamous
carcinoma in situ) and those diagnosed as (viii) ICC, which
comprises both squamous cell carcinoma, adeno/adenosquamous
carcinoma or cervical cancer of other/unspeciﬁed histology.Statistical analysis
Overall HPV DNA prevalence is reported as a percentage of all
women tested by consensus PCR, in descending order of their
frequency of detection in ICC. Each HPV type was evaluated
independently. Type-speciﬁc positivity was estimated only among
those studies that both genotyped and reported the prevalence of
the HPV type in question, and thus, denominators vary by type.
Type-speciﬁc positivity includes that contributed by multiple HPV
infections. The results have previously been published in more
detail for the major 13 oncogenic HPV types (Guan et al., 2012).Cutaneous HPV types
Identiﬁcation of studies
We searched PubMed for studies published up to 12th of May
of 2013, using the search terms “Human papillomavirus” and
“HPV” with the combination of “cutaneous” and “skin”. All of the
identiﬁed studies were cross-referenced to search for studies
missed by the PubMed search.
D. Bzhalava et al. / Virology 445 (2013) 224–231230Inclusion/exclusion criteria
All studies that provided analyses on exposures to cutaneous
HPV types and risk of non-melanoma skin cancers, recorded
separately for SCC of the skin, BCC or for AK, which is considered
as a premalignant skin lesion. Studies that did not compare
healthy and diseased individuals, merely reporting cutaneous
HPV sequences and studies reporting case groups other than skin
cancers were excluded, as well as review papers. If several studies
reported on the same population, the study that was most recently
published was chosen.
Data extraction
From the identiﬁed studies data was extracted on the number
of diseased subjects and their healthy controls by cutaneous HPV
type exposure status, by the laboratory method of exposure
identiﬁcation and by types of skin cancers.
Statistical analysis
We used the “meta” package from the statistical software R
(www.r-project.org) to estimate summary effect estimates. Both
ﬁxed- and random-effects models were used and we weighed
each study by the inverse variance method.
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